Immunotherapy agent promising in NSCLC
GENEVA-Patients with NSCLC who received MAGE-A3 ASCI (antigen-specific cancer immunotherapeutic) had longer disease-free (HR 0.76) and overall survival (HR 0.81) than those who received placebo, although in this phase II study of 182 patients, the difference did not reach significance.
GENEVA-Patients with NSCLC who received MAGE-A3 ASCI (antigen-specific cancer immunotherapeutic) had longer disease-free (HR 0.76) and overall survival (HR 0.81) than those who received placebo, although in this phase II study of 182 patients, the difference did not reach significance. Johan Vansteenkiste, MD, PhD, of University Hospital Gasthuisberg, Belgium, reported the results, with 44 months of follow-up, at the 1st European Lung Cancer Conference (abstract 1480). An efficacy phase III study (MAGRIT) is ongoing.
Highlighting Insights From the Marginal Zone Lymphoma Workshop
Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.
